A CRISPR-Cas9 Generated MDCK Cell Line Expressing Human MDR1 Without Endogenous Canine MDR1 (cABCB1): An Improved Tool for Drug Efflux Studies.

Madin-Darby canine kidney (MDCK) II cells stably transfected with transport proteins are commonly used models for drug transport studies. However, endogenous expression of especially canine MDR1 (cMDR1) confounds the interpretation of such studies. Here we have established an MDCK cell line stably overexpressing the human MDR1 transporter (hMDR1; P-glycoprotein), and used CRISPR-Cas9 gene editing to knockout the endogenous cMDR1. Genomic screening revealed the generation of a clonal cell line homozygous for a 4-nucleotide deletion in the canine ABCB1 gene leading to a frameshift and a premature stop codon. Knockout of cMDR1 expression was verified by quantitative protein analysis and functional studies showing retained activity of the human MDR1 transporter. Application of this cell line allowed unbiased reclassification of drugs previously defined as both substrates and non-substrates in different studies using commonly used MDCK-MDR1 clones. Our new MDCK-hMDR1 cell line, together with a previously developed control cell line, both with identical deletions in the canine ABCB1 gene and lack of cMDR1 expression represent excellent in vitro tools for use in drug discovery.

[1]  Karen Methling,et al.  Metabolic activation and analgesic effect of flupirtine in healthy subjects, influence of the polymorphic NAT2, UGT1A1 and GSTP1. , 2015, British journal of clinical pharmacology.

[2]  Ying Wang,et al.  Kinetic analysis of human and canine P-glycoprotein-mediated drug transport in MDR1-MDCK cell model: approaches to reduce false-negative substrate classification. , 2013, Journal of pharmaceutical sciences.

[3]  R L Juliano,et al.  A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. , 1976, Biochimica et biophysica acta.

[4]  J. Polli,et al.  Rational use of in vitro P-glycoprotein assays in drug discovery. , 2001, The Journal of pharmacology and experimental therapeutics.

[5]  B. Rothen‐Rutishauser,et al.  P-Glycoprotein in cell cultures: a combined approach to study expression, localisation, and functionality in the confocal microscope. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[6]  J. Dukes,et al.  The MDCK variety pack: choosing the right strain , 2011, BMC Cell Biology.

[7]  M. Niemi,et al.  Membrane transporters in drug development , 2010, Nature Reviews Drug Discovery.

[8]  L Zhang,et al.  Transporter Studies in Drug Development: Experience to Date and Follow‐Up on Decision Trees From the International Transporter Consortium , 2013, Clinical pharmacology and therapeutics.

[9]  P. Verhoest,et al.  Defining desirable central nervous system drug space through the alignment of molecular properties, in vitro ADME, and safety attributes. , 2010, ACS chemical neuroscience.

[10]  J. König,et al.  Double‐transfected MDCK cells expressing human OCT1/MATE1 or OCT2/MATE1: determinants of uptake and transcellular translocation of organic cations , 2011, British journal of pharmacology.

[11]  I. Hidalgo,et al.  Evaluation of the MDR-MDCK cell line as a permeability screen for the blood-brain barrier. , 2005, International journal of pharmaceutics.

[12]  P. Artursson,et al.  In Vitro Characterization of Interactions with Drug Transporting Proteins , 2013 .

[13]  T. Celius,et al.  Stable suppression of MDR1 gene expression and function by RNAi in Caco-2 cells. , 2004, Biochemical and biophysical research communications.

[14]  P. Borst,et al.  Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[15]  J. Donovan,et al.  Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein , 2006, Psychopharmacology.

[16]  T. Abe,et al.  Transcellular Transport of Organic Anions Across a Double-transfected Madin-Darby Canine Kidney II Cell Monolayer Expressing Both Human Organic Anion-transporting Polypeptide (OATP2/SLC21A6) and Multidrug Resistance-associated Protein 2 (MRP2/ABCC2)* , 2002, The Journal of Biological Chemistry.

[17]  M. Gottesman,et al.  Multidrug resistance in cancer: role of ATP–dependent transporters , 2002, Nature Reviews Cancer.

[18]  G. Fricker,et al.  Establishment of optimized MDCK cell lines for reliable efflux transport studies. , 2014, Journal of pharmaceutical sciences.

[19]  Li Di,et al.  Development of a new permeability assay using low-efflux MDCKII cells. , 2011, Journal of pharmaceutical sciences.

[20]  Genomic Knockout of Endogenous Canine P-Glycoprotein in Wild-Type, Human P-Glycoprotein and Human BCRP Transfected MDCKII Cell Lines by Zinc Finger Nucleases , 2015, Pharmaceutical Research.

[21]  D. Keppler,et al.  Vectorial transport by double-transfected cells expressing the human uptake transporter SLC21A8 and the apical export pump ABCC2. , 2001, Molecular pharmacology.

[22]  Tudor I. Oprea,et al.  Improving the prediction of the brain disposition for orally administered drugs using BDDCS. , 2012, Advanced drug delivery reviews.

[23]  Wolfgang Löscher,et al.  Differences in the expression of endogenous efflux transporters in MDR1‐transfected versus wildtype cell lines affect P‐glycoprotein mediated drug transport , 2010, British journal of pharmacology.

[24]  I. Pastan,et al.  A retrovirus carrying an MDR1 cDNA confers multidrug resistance and polarized expression of P-glycoprotein in MDCK cells. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[25]  Yong Li,et al.  Targeting ABCB1-mediated tumor multidrug resistance by CRISPR/Cas9-based genome editing. , 2016, American journal of translational research.

[26]  G. M. Pollack,et al.  Kinetic Considerations for the Quantitative Assessment of Efflux Activity and Inhibition: Implications for Understanding and Predicting the Effects of Efflux Inhibition , 2007, Pharmaceutical Research.

[27]  T. Iwatsubo,et al.  Effects of aripiprazole and its active metabolite dehydroaripiprazole on the activities of drug efflux transporters expressed both in the intestine and at the blood–brain barrier , 2012, Biopharmaceutics & drug disposition.

[28]  Maria Backlund,et al.  Complete Knockout of Endogenous Mdr1 (Abcb1) in MDCK Cells by CRISPR-Cas9. , 2016, Journal of pharmaceutical sciences.

[29]  J. Markowitz,et al.  In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. , 2002, Life sciences.